QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=F4385810A2F853500584F0F0A41AFC98;jsessionid=402D433726765B5E0B4B53C5ECFF39F8;jsessionid=2672DE7710AE37FB169E91C1E78BBB45;jsessionid=0E4706BFF4DFC9F47B26EE16780EF307;jsessionid=06B0C01B431307558A11B3499877A52B;jsessionid=376BF7EB44A9FD197A4897EAB5110927;jsessionid=321E40428FEA63EF0536BF1475C70C90 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=3D6E4177C1A2C936A25F58E22CF119FE;jsessionid=0445342AB54FB9C9C8E9FC6C5F300B7E;jsessionid=AC7337EA37965DE0DF9EC46EE60C3E6B;jsessionid=F4385810A2F853500584F0F0A41AFC98;jsessionid=402D433726765B5E0B4B53C5ECFF39F8;jsessionid=2672DE7710AE37FB169E91C1E78BBB45;jsessionid=0E4706BFF4DFC9F47B26EE16780EF307;jsessionid=06B0C01B431307558A11B3499877A52B;jsessionid=376BF7EB44A9FD197A4897EAB5110927;jsessionid=321E40428FEA63EF0536BF1475C70C90